DETERMINE Trial Treatment Arm 5: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05768178 |
|
Recruitment Status :
Recruiting
First Posted : March 14, 2023
Last Update Posted : March 14, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma.
Cobimetinib and vemurafenib work in patients with these types of cancers which have certain changes in the cancer cells called BRAF V600 mutation-positive.
Investigators now wish to find out if it will be useful in treating patients with other cancer types which are also BRAF V600 mutation-positive. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.
This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Solid Tumor Haematological Malignancy Melanoma Thyroid Cancer, Papillary Ovarian Neoplasms Colorectal Neoplasms Laryngeal Neoplasms Carcinoma, Non-Small-Cell Lung Glioma Multiple Myeloma Erdheim-Chester Disease Thyroid Carcinoma, Anaplastic | Drug: Vemurafenib Drug: Cobimetinib | Phase 2 Phase 3 |
DETERMINE Treatment arm 5 (vemurafenib and Cobimetinib) aims to evaluate the efficacy of vemurafenib and cobimetinib in adult patients with rare* cancers with BRAF V600 mutations or in common cancers where BRAFV600 mutations and considered to be infrequent.
*Rare is defined generally as incidence less than 6 cases in 100,000 patients or common cancers with rare alterations.
This treatment arm has a target sample size of 30 evaluable patients. Sub-cohorts may be defined and further expanded where promising activity is identified to a target of 30 evaluable patients each.
The ultimate aim is to translate positive clinical findings to the NHS (Cancer Drugs Fund) to provide new treatment options for rare adult cancers.
OUTLINE:
Pre-screening: The Molecular Tumour Board makes a treatment recommendation for the participant based on molecularly-defined cohorts.
Screening: Consenting participants undergo biopsy and collection of blood samples for research purposes.
Treatment: Participants will receive vemurafenib and cobimetinib until disease progression, unacceptable toxicity or withdrawal of consent. Participants will also undergo collection of blood samples at various intervals while receiving treatment and at EoT.
After completion of study treatment, patients are followed up every 3 months for 2 years.
THE DETERMINE TRIAL MASTER (SCREENING) PROTOCOL:
Please see DETERMINE Trial Master (Screening) Protocol record (NCT05722886) for information on the DETERMINE Trial Master Protocol and applicable documents.
| Study Type : | Interventional |
| Estimated Enrollment : | 30 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations Treatment Arm 5: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. |
| Estimated Study Start Date : | March 2023 |
| Estimated Primary Completion Date : | October 2029 |
| Estimated Study Completion Date : | October 2029 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment Arm 5- Vemurafenib and Cobimetinib
This vemurafenib and cobimetinib appendix is for BRAF V600 mutation-positive malignancies occurring in adults.
|
Drug: Vemurafenib
Participants will receive vemurafenib at a dose of 960 mg orally on a twice daily schedule throughout a 28-day cycle.
Other Name: Zelboraf Drug: Cobimetinib Participants will receive cobimetinib at a dose of 60 mg (3 tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.
Other Name: Cotellic |
- Objective Response (OR) [ Time Frame: Disease assessments to be performed up to 24 weeks from the start of trial treatment. ]An OR is defined as the confirmed occurrence of either a Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 criteria (or immune related (ir)-RECIST or standard imaging criteria for specific disease e.g. Response Evaluation in Neuro Oncology criteria (RANO)). In patients with leukaemia, OR will be defined as the occurrence of CR , CRi (CR incomplete neutrophil recovery) or CRp (CR with incomplete platelet recovery). The trial will report the proportion of patients with an OR and 95% credible interval.
- Durable Clinical Benefit (DCB) [ Time Frame: Disease assessments to be performed up to 24 weeks from the start of trial treatment. ]DCB is defined as the absence of disease progression for at least 24 weeks from the start of trial treatment according to RECIST Version 1.1 criteria (or ir-RECIST or standard imaging criteria for specific disease e.g. RANO criteria). Alternative definitions of DCB based on different time points may be pre-specified for particular sub-cohorts if 24 weeks is not clinically relevant. The trial will report the proportion of patients with a DCB and 95% credible interval.
- Duration of response (DR) [ Time Frame: Disease assessment every 2 cycles (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 3 cycles, on discussion with Sponsor. Follow-up visits occur every 12 weeks after last dose of vemurafenib and cobimetinib for up to 2 years. ]Duration of response, is defined as the time from the date of the first confirmed CR or PR according to RECIST 1.1 or ir-RECIST or standard imaging criteria for specific disease e.g. RANO criteria to the date of disease progression. The trial will report the median DR and 95% credible interval.
- Best percentage change in sum of target lesion / index lesion diameters (PCSD) [ Time Frame: Disease assessment performed every 2 cycles (each cycle is 28 days). After 24 weeks, disease assessments can be repeated every 3 cycles, on discussion with Sponsor. Follow-up visits are every 12 weeks following last dose for a period of up to 2 years. ]PCSD is defined as the greatest decrease or least increase in the sum of target lesion diameters (RECIST) or index lesion diameters (irRECIST) as a percentage compared to the baseline measurement. The trial will report the mean PCSD and 95% credible interval.
- Time to treatment discontinuation (TTD) [ Time Frame: From first dose of vemurafenib and cobimetinib to discontinuation of trial treatment up to 5 years. ]TTD is defined as the time from date of starting trial treatment to date of discontinuing trial treatment, in days estimated by the median of the posterior inverse gamma probability distribution. The trial will report the median TTD and 95% credible interval.
- Progression-Free Survival time (PFS) [ Time Frame: Disease assessment performed every 2 cycles (each cycle is 28 days). After 24 weeks, it can be done every 3 cycles, on discussion with Sponsor. Follow-up visits are every 12 weeks after last dose of vemurafenib and cobimetinib for up to 2 years. ]PFS is defined as the time from date of starting trial treatment to date of progression or date of death without a previous progression recorded estimated by the median of the posterior inverse gamma probability distribution.
- Time to Progression (TTP) [ Time Frame: Disease assessment performed every 2 cycles (each cycle is 28 days). After 24 weeks, it can be done every 3 cycles, on discussion with Sponsor. Follow-up visits are every 12 weeks after last dose of vemurafenib and cobimetinib for up to 2 years. ]TTP is defined as the time from date of starting trial treatment to date of progression or date of death without recorded progression censored rather than events. The trial will report the median TTP and 95% credible interval.
- Growth Modulation Index (GMI) [ Time Frame: Disease assessment performed every 2 cycles (each cycle is 28 days). After 24 weeks, it can be done every 3 cycles, on discussion with Sponsor. Follow-up visits are every 12 weeks after last dose of vemurafenib and cobimetinib for up to 2 years. ]GMI is defined as the ratio of TTP with the trial protocol treatment to TTP on the most recent prior line of therapy. The trial will report the mean GMI and 95% credible interval.
- Overall Survival time (OS) [ Time Frame: Time of death or up to 2 years after the End of Treatment (EoT) visit. ]OS is defined as the time from date of starting trial treatment to date of death from any cause estimated by the median of the posterior normal probability distribution.
- Occurrence of at least one Suspected Unexpected Serious Adverse Event (SUSAR) [ Time Frame: From the time of consent until 28 days after last dose of vemurafenib or cobimetinib (up to 5 years) or until patient starts another anti-cancer therapy. An average time frame will be presented with results entry. ]The trial will report the number of patients who experience at least one SUSAR to vemurafenib and cobimetinib.
- Occurrence of at least one Grade 3, 4 or 5 vemurafenib and cobimetinib related AE [ Time Frame: From the time of consent until 28 days after last dose of vemurafenib or cobimetinib (up to 5 years) or until patient starts another anti-cancer therapy. An average time frame will be presented with results entry. ]Number of patients who experience at least one vemurafenib and cobimetinib related Grade 3, 4 or 5 AE according to NCI CTCAE Version 5.0.
- EORTC-QLQ-30 Standardised Area Under Summary Score Curve (QLQSAUC) [ Time Frame: QoL surveys performed at baseline every 2 cycles (every cycle is 28 days) and after interrupting treatment (up to 5 years). ]Multiple measures of QoL will be generated from patient completion of the European Organisation for Research and Treatment of Cancer QLQC30 (EORTC-QLQC30) questionnaire (30 measures). For each patient the Summary Score from the questionnaire will be generated at each time point and the area under the curve generated by these scores over time will be calculated and standardised by the time frame. The trial will report the mean QLQSAUC and 95% credible interval.
- EQ-5D Standardised Area Under Index Value Curve (EQ5DSAUC) [ Time Frame: QoL surveys performed prior to inclusion, every 2 cycles (each cycle is 28 days) and at EoT visit (up to 5 years). ]Two measures of QoL will be generated from patient completion of the EQ-5D-5L questionnaire. For each measure, scores based on responses from the questionnaire will be generated at each time point and the area under the curve generated by these scores over time will be calculated and standardised by the time frame. The trial will report the mean EQ5DSAUC and 95% credible interval.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
A. Confirmed diagnosis of a malignancy harbouring any actionable BRAF V600 mutation using an analytically validated sequencing technique (result does not need to be confirmed at screening unless not tested within 18 months, in which case, repeat analysis is required).
B. Adult patients ≥16 years old.
C. Patients must be able and willing to undergo a fresh biopsy.
D. Adequate organ function as per haematological and biochemical indices within the ranges shown below. These measurements should be performed to confirm the patient's eligibility.
Haemoglobin (Hb): ≥90 g/L (transfusion allowed)
Absolute neutrophil count (ANC): ≥1.5×10^9/L (no granulocyte colony-stimulating factor [GCSF] support in preceding 72 hours)
Platelet count: ≥100×10^9/L (unsupported for 72 hours)
Bilirubin: <1.5 x upper limit of normal (ULN)
Patients with known Gilbert disease: total bilirubin ≤3.0 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): ≤2.5 x ULN or ≤ 5 ULN if raised due to presence of liver metastases
estimated glomerular filtration rate (eGFR): ≥30 mL/min (uncorrected value)
Coagulation- Prothrombin (PT) (or international normalized ratio (INR), and activated partial thromboplastin clotting time (aPTT): INR or PT ≤1.5 and aPTT <1.5x ULN (unless patient is on anticoagulants e.g. warfarin [INR should be stable and within therapeutic range], or direct oral anticoagulants [DOAC]
Electrolytes- Potassium (K), Magnesium (Mg) and Calcium (Ca): Electrolytes within normal range (electrolyte replacement permitted)
E. Women of childbearing potential are eligible provided that they meet the following criteria:
- Have a negative serum or urine pregnancy test before enrolment and;
-
Agree to use any two forms of highly effective or effective methods together (at least one to be non-hormonal) such as:
- Highly effective methods:
- combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
- progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
- intrauterine device (IUD)
- intrauterine hormone-releasing system (IUS)
- bilateral tubal occlusion
- vasectomised partner
-
sexual abstinence
- Effective methods:
- progestogen-only oral hormonal contraception not associated with inhibition of ovulation
- male or female condom with or without spermicide
- cap, diaphragm or sponge with spermicide
Effective from the first administration of vemurafenib or cobimetinib (whichever is first), throughout the trial and for six months after the last administration of vemurafenib or cobimetinib (whichever is later).
F. Male patients with partners who are women of childbearing potential, are eligible provided that they agree to the following, from the first administration of vemurafenib or cobimetinib (whichever is first), throughout the trial and for six months after the last administration of vemurafenib or cobimetinib (whichever is later):
- Agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence
- Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses a highly effective method of contraception as in E, above.
- Male patients with pregnant or lactating partners must be advised to use barrier method contraception (for example, condom plus spermicide) to prevent drug exposure of the foetus or neonate.
Exclusion Criteria:
A. Diagnosis of unresectable or metastatic melanoma with a BRAF V600 mutation.
B. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or for six months following their last dose of vemurafenib or cobimetinib, whichever is later.
C. Patients with QTcF (Corrected QT interval by Fridericia) at screening of >450ms for males and >470ms for females measured on triplicate ECG (if 1/3 readings show >450/470ms then patient is ineligible).
D. Patients with any history of long QT syndrome or Torsades de Pointes (or any concurrent medication with a known risk of inducing Torsades de Pointes).
E. Known hypersensitivity to vemurafenib or cobimetinib or any of the excipients.
F. Patients with clinically significant pre-existing cardiac conditions including (within the last three months prior to screening):
- Uncontrolled or symptomatic angina,
- Uncontrolled atrial or ventricular arrhythmias,
- Class III & IV New York Heart Association (NYHA) congestive heart failure,
- Left ventricular ejection fraction (LVEF) <50%,
- Myocardial infarction
G. Ophthalmological disorders: History of retinal detachment, severe visual impairment, central serous chorioretinopathy, neovascular retinopathy, or retinopathy of prematurity.
Patients with low grade gliomas causing visual impairment may be considered eligible and monitored with close ophthalmological monitoring.
H. History of pancreatitis.
I. History of central nervous system (CNS) or gastrointestinal (GI) haemorrhage within three months of trial entry.
J. Patients with any history of haemorrhagic stroke.
K. Prior treatment with the same class of drug unless presence of a resistance alteration known to be potentially sensitive to either vemurafenib or cobimetinib. Prior sorafenib use is permissible following a washout period of 10 days.
L. Patients with rapidly progressing or symptomatically deteriorating brain metastases. Patients with previously treated brain metastases are eligible, provided the patient has not experienced a seizure or had a clinically significant change in neurological status within the 14 days prior to the start of IMP administration. Such patients must be non-dependent on steroids or on a stable or reducing dose of steroid treatment for at least 14 days prior to the start of IMP administration. Primary brain or CNS malignancies are allowed providing the patient is clinically stable (if requiring corticosteroids must be at stable or decreasing doses for at least 14 days prior to the start of IMP administration). Patients who have received brain irradiation must have completed whole-brain radiotherapy and/or stereotactic radiosurgery at least 14 days prior to the start of IMP administration.
M. Any clinically significant concomitant disease or condition (or it's treatment) that could interfere with, the conduct of the trial or absorption of oral medications that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05768178
| Contact: Aida Sarmiento Castro | +442034695101 | determine@cancer.org.uk |
Show 17 study locations
| Principal Investigator: | Matthew Krebs | The Christie Hospital |
| Responsible Party: | Cancer Research UK |
| ClinicalTrials.gov Identifier: | NCT05768178 |
| Other Study ID Numbers: |
CRUKD/21/004- Treatment Arm 5 IRAS ID: 1004057 ( Other Identifier: IRAS ) |
| First Posted: | March 14, 2023 Key Record Dates |
| Last Update Posted: | March 14, 2023 |
| Last Verified: | March 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Individual de-identified patient data will be shared with researchers whose proposed use of the data is approved by a review committee of the Sponsor. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
| Time Frame: | All requests for data relating to this treatment arm that are made within 5 years from last patient last visit for the vemurafenib and cobimetinib treatment arm will be considered; requests made subsequently will be considered where possible. |
| Access Criteria: | When a request has been approved, Cancer Research UK will provide access to the de-identified individual patient-level data and appropriate supporting information. A signed Data Sharing Agreement must be in place before accessing requested information. Requests should be submitted to drugdev@cancer.org.uk. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Adult Antineoplastic Agents Cancer Malignancy Malignant Neoplasms Molecular Targeted Therapy Mutation Neoplasms by Histologic Type |
Neoplasms by Site Precision Medicine Cobimetinib Proto-Oncogene Proteins B-raf Rare Tumour-agnostic Vemurafenib |
|
Ovarian Neoplasms Carcinoma Neoplasms Multiple Myeloma Thyroid Neoplasms Colorectal Neoplasms Carcinoma, Non-Small-Cell Lung Hematologic Neoplasms Laryngeal Neoplasms Thyroid Cancer, Papillary Thyroid Carcinoma, Anaplastic Erdheim-Chester Disease Thyroid Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms, Plasma Cell Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Endocrine System Diseases Endocrine Gland Neoplasms Neoplasms by Site Head and Neck Neoplasms |